A Phase 2 interventional study of Canakinumab and Pembrolizumab in Non-small Cell Lung Cancer, sponsored by Novartis Pharmaceuticals. Terminated at 29 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung — 29 open to participants now, 48 under way, 13 of them phase 3. pembrolizumab · Carcinoma, Non-Small-Cell Lung.
Among the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, this one is the 58th largest by enrollment, is one of 8 that started in 2019, is one of 65 in phase 2, and was the 64th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →29 of the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung are open now, in 10 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
EuroCityClinic LLC · Sites in Russia
Ages 18+
AHS Cancer Control Alberta · Sites in Canada
Ages 18+
UNICANCER · Sites in France
Ages 18+
Hunan Province Tumor Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 74 · Phase 3 30 · Phase 4 1
First in 2013; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 65 across the 127 interventional studies. Of the 67 that completed or were terminated, 56 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 127 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
101 studies in Carcinoma, Non-Small-Cell Lung by Novartis: 8 open now, 15 under way, none of them phase 3. Of 77 finished, 39 (51%) have results posted.
Among the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, this one is the 48th largest by enrollment of the 92 interventional ones that give a count, is one of 4 that started in 2019, is one of 30 in phase 2, and was the 68th registered.
Novartis’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1998.
13 of the studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT04380636Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | 2027-05-05 |
| NCT05085028Phase 3Imperial College LondonA Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | 2027-05-31 |
| NCT05493566Emory UniversityLow-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer | 2027-01-07 |
| NCT06388031Peking Union Medical College HospitalICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI | 2027-01-10 |
Add all 13 to your calendar (.ics) → With an account.
Among the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Novartis’s 101 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR of pembrolizumab as a single agent and the dynamic of the tumor microenvironment changes on treatment.
This was a randomized, phase II, open-label study evaluating canakinumab, an anti-IL-1β monoclonal antibody, or pembrolizumab, a monoclonal antibody designed to block the PD-1 receptor, as monotherapy or in combination as neoadjuvant therapy. The study population included adult subjects with resectable non-small cell lung cancer (NSCLC) planned for surgery in approximately 4-6 weeks. Subjects were treated for a maximum duration of 6 weeks (2 cycles) until surgery, progression, unacceptable toxicity or discontinuation from the study treatment for any other reason.
Subjects were randomized in a 2:2:1 ratio to one of the 3 treatment arms (canakinumab alone or canakinumab in combination with pembrolizumab or pembrolizumab alone). Surgery was performed between 4 to 6 weeks after the first dose of study treatment.
All randomized subjects were followed for safety for up to 130 days following the last dose of study treatment (safety follow-up period).
Key inclusion criteria:
Key exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200 mg of canakinumab once every 3 weeks for a maximum duration of 6 weeks prior to surgery
Drug: Canakinumab
Participants received 200 mg of canakinumab in combination with 200 mg of pembrolizumab once every 3 weeks for a maximum duration of 6 weeks prior to surgery
Drug: Canakinumab · Drug: Pembrolizumab
Participants received 200 mg of pembrolizumab every 3 weeks for a maximum duration of 6 weeks prior to surgery
Drug: Pembrolizumab
200 mg of canakinumab administered via subcutaneous injections once every 3 weeks for a maximum duration of 6 weeks
Also known as: ACZ885
200 mg of pembrolizumab administered via infusion once every 3 weeks for a maximum duration of 6 weeks
Major Pathological Response (MPR) Rate at the Time of Surgery in Subjects Randomized to Canakinumab Monotherapy and in Combination With Pembrolizumab Based on Central Review
MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR was assessed at the time of surgery in all subjects randomized to canakinumab monotherapy and in combination with pembrolizumab based on central review.
Time frame: At time of surgery (up to 6 weeks after first dose of study treatment)
Canakinumab Antidrug Antibodies (ADA) Prevalence
Canakinumab ADA prevalence at baseline was calculated as the percentage of participants who had a canakinumab ADA positive result at baseline
Time frame: Predose (0 hour) on Day 1 of Cycle 1 (Cycle=21 days)
Canakinumab ADA Incidence
Canakinumab ADA incidence on treatment was calculated as the percentage of participants who were canakinumab treatment-induced ADA positive (post-baseline ADA positive with ADA-negative sample at baseline) and canakinumab treatment-boosted ADA positive (post-baseline ADA positive with titer that is at least the fold titer change greater than the ADA-positive baseline titer)
Time frame: From baseline (Predose on Day 1 of Cycle 1) up to 130 days after last dose of study treatment (assessed up to 24.6 weeks). Cycle = 21 days
Pembrolizumab ADA Prevalence
Pembrolizumab ADA prevalence at baseline was calculated as the percentage of participants who had a pembrolizumab ADA positive result at baseline
Time frame: Predose (0 hour) on Day 1 of Cycle 1 (Cycle = 21 days)
Pembrolizumab ADA Incidence
Pembrolizumab ADA incidence on treatment was calculated as the percentage of participants who were pembrolizumab treatment-induced ADA positive (post-baseline ADA positive with ADA-negative sample at baseline) and pembrolizumab treatment-boosted ADA positive (post-baseline ADA positive with titer that is at least the fold titer change greater than the ADA-positive baseline titer)
Time frame: From baseline (Predose on Day 1 of Cycle 1) up to 26 days after last dose of study treatment (assessed up to 10.7 weeks). Cycle = 21 days
Overall Response Rate (ORR) Based on Local Investigator Assessment Using RECIST v1.1
ORR is defined as the percentage of subjects with confirmed best overall response of complete response (CR) or partial response (PR), as per local investigator's assessment by RECIST 1.1. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters
Time frame: From date of randomization to date of surgery, assessed up to 6 weeks
Serum Canakinumab Concentration
Canakinumab serum concentrations were determined at the specified time points.
Time frame: Predose (0 hour) on Day 1 of Cycles 1 and 2 (Cycle =21 days)
Serum Pembrolizumab Concentration
Pembrolizumab serum concentrations were determined at the specified time points.
Time frame: Predose (0 hour) and 0.5 hours post dose on Day 1 of Cycle 1 and predose on Cycle 2 (Cycle =21 days)
Surgical Feasibility Rate
Surgical feasibility rate was defined as the percentage of subjects who underwent surgery following study treatment.
Time frame: Up to 6 weeks after first dose
Major Pathological Response (MPR) Rate at the Time of Surgery in Subjects Randomized to Pembrolizumab Monotherapy Based on Central Review
MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR was assessed at the time of surgery in all subjects randomized to pembrolizumab monotherapy arm based on central review.
Time frame: At time of surgery (up to 6 weeks after first dose)
Difference in Major Pathological Response (MPR) Rate Between the Canakinumab Plus Pembrolizumab Arm and the Pembrolizumab Arm Based on Central Review
MPR was defined as the percentage of participants with ≤10% residual viable tumor cells on surgical samples. MPR was assessed at the time of surgery based on central review. The difference in MPR rate between the canakinumab plus pembrolizumab arm and the pembrolizumab arm based on central review along with the Chang and Zhang confidence interval was assessed.
Time frame: At time of surgery (up to 6 weeks after first dose of study treatment)
Major Pathological Response (MPR) Rate at the Time of Surgery in All Subjects Based on Local Review
MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR was assessed at the time of surgery in all subjects based on local review.
Time frame: At time of surgery (up to 6 weeks after first dose)
Major Pathological Response (MPR) Rate Based on the Levels of Biomarkers
MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR rate was analyzed by the biomarker subgroups at baseline. Biomarkers included PD-L1, CD8, hs-CRP and hs-IL-6.
Time frame: From date of randomization up to 6 weeks after first dose
The study was conducted in 29 centers across 12 countries.
| Milestone | Canakinumab Monotherapy | Canakinumab + Pembrolizumab | Pembrolizumab Monotherapy |
|---|---|---|---|
| Started | 35 | 35 | 18 |
| Completed | 35 | 35 | 17 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Milestone | Canakinumab Monotherapy | Canakinumab + Pembrolizumab | Pembrolizumab Monotherapy |
|---|---|---|---|
| Started | 35 | 35 | 18 |
| Completed | 30 | 32 | 17 |
| Not completed | 5 | 3 | 1 |
| Withdrew: Death | 3 | 2 | 1 |
| Withdrew: Subject decision | 2 | 1 | 0 |
MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR was assessed at the time of surgery in all subjects randomized to canakinumab monotherapy and in combination with pembrolizumab based on central review.
| Percentage of participants | Canakinumab Monotherapy | Canakinumab + Pembrolizumab |
|---|---|---|
| Major Pathological Response (MPR) Rate at the Time of Surgery in Subjects Randomized to Canakinumab Monotherapy and in Combination With Pembrolizumab Based on Central Review | 2.9 (0.07 to 14.92) | 17.1 (6.56 to 33.65) |
Canakinumab ADA prevalence at baseline was calculated as the percentage of participants who had a canakinumab ADA positive result at baseline
| Participants | Canakinumab Monotherapy | Canakinumab + Pembrolizumab |
|---|---|---|
| Canakinumab Antidrug Antibodies (ADA) Prevalence | 0 | 0 |
Canakinumab ADA incidence on treatment was calculated as the percentage of participants who were canakinumab treatment-induced ADA positive (post-baseline ADA positive with ADA-negative sample at baseline) and canakinumab treatment-boosted ADA positive (post-baseline ADA positive with titer that is at least the fold titer change greater than the ADA-positive baseline titer)
| Participants | Canakinumab Monotherapy | Canakinumab + Pembrolizumab |
|---|---|---|
| Canakinumab ADA Incidence | 1 | 0 |
Pembrolizumab ADA prevalence at baseline was calculated as the percentage of participants who had a pembrolizumab ADA positive result at baseline
| Participants | Canakinumab + Pembrolizumab | Pembrolizumab Monotherapy |
|---|---|---|
| Pembrolizumab ADA Prevalence | 4 | 3 |
Pembrolizumab ADA incidence on treatment was calculated as the percentage of participants who were pembrolizumab treatment-induced ADA positive (post-baseline ADA positive with ADA-negative sample at baseline) and pembrolizumab treatment-boosted ADA positive (post-baseline ADA positive with titer that is at least the fold titer change greater than the ADA-positive baseline titer)
| Participants | Canakinumab + Pembrolizumab | Pembrolizumab Monotherapy |
|---|---|---|
| Pembrolizumab ADA Incidence | 3 | 4 |
ORR is defined as the percentage of subjects with confirmed best overall response of complete response (CR) or partial response (PR), as per local investigator's assessment by RECIST 1.1. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters
| Percentage of participants | Canakinumab Monotherapy | Canakinumab + Pembrolizumab | Pembrolizumab Monotherapy |
|---|---|---|---|
| Overall Response Rate (ORR) Based on Local Investigator Assessment Using RECIST v1.1 | 0 (0.00 to 10.00) | 8.6 (1.80 to 23.06) | 11.1 (1.38 to 34.71) |
Canakinumab serum concentrations were determined at the specified time points.
| microgram/miliLiter (ug/mL) | Canakinumab Monotherapy | Canakinumab + Pembrolizumab |
|---|---|---|
| Cycle 1 | 0 ± 0 | 0 ± 0 |
| Cycle 2 | 10.9 ± 32.9 | 10.3 ± 41.0 |
Pembrolizumab serum concentrations were determined at the specified time points.
| ug/mL | Canakinumab + Pembrolizumab | Pembrolizumab Monotherapy |
|---|---|---|
| Cycle 1 predose | 0 ± 0 | 0 ± 0 |
| Cyle 1 0.5 hours post dose | 65.5 ± 23.8 | 65.5 ± 19.9 |
| Cycle 2 predose | 16.0 ± 43.4 | 35.5 ± 13.7 |
Surgical feasibility rate was defined as the percentage of subjects who underwent surgery following study treatment.
| Percentage of participants | Canakinumab Monotherapy | Canakinumab + Pembrolizumab | Pembrolizumab Monotherapy |
|---|---|---|---|
| Surgical Feasibility Rate | 91.4 (76.94 to 98.20) | 97.1 (85.08 to 99.93) | 100 (81.47 to 100.00) |
MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR was assessed at the time of surgery in all subjects randomized to pembrolizumab monotherapy arm based on central review.
| Percentage of participants | Pembrolizumab Monotherapy |
|---|---|
| Major Pathological Response (MPR) Rate at the Time of Surgery in Subjects Randomized to Pembrolizumab Monotherapy Based on Central Review | 16.7 (3.58 to 41.42) |
MPR was defined as the percentage of participants with ≤10% residual viable tumor cells on surgical samples. MPR was assessed at the time of surgery based on central review. The difference in MPR rate between the canakinumab plus pembrolizumab arm and the pembrolizumab arm based on central review along with the Chang and Zhang confidence interval was assessed.
| Percentage of participants | Canakinumab + Pembrolizumab | Pembrolizumab Monotherapy |
|---|---|---|
| Difference in Major Pathological Response (MPR) Rate Between the Canakinumab Plus Pembrolizumab Arm and the Pembrolizumab Arm Based on Central Review | 17.1 (6.56 to 33.65) | 16.7 (3.58 to 41.42) |
MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR was assessed at the time of surgery in all subjects based on local review.
| Percentage of participants | Canakinumab Monotherapy | Canakinumab + Pembrolizumab | Pembrolizumab Monotherapy |
|---|---|---|---|
| Major Pathological Response (MPR) Rate at the Time of Surgery in All Subjects Based on Local Review | 0 (0.00 to 10.00) | 20.0 (8.44 to 36.94) | 22.2 (6.41 to 47.64) |
MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR rate was analyzed by the biomarker subgroups at baseline. Biomarkers included PD-L1, CD8, hs-CRP and hs-IL-6.
| Percentage of participants | Canakinumab Monotherapy | Canakinumab + Pembrolizumab | Pembrolizumab Monotherapy |
|---|---|---|---|
| PD-L1: <1% | 0 (0.00 to 26.46) | 7.1 (0.18 to 33.87) | 14.3 (0.36 to 57.87) |
| PD-L1: 1-49% | 6.7 (0.17 to 31.95) | 15.4 (1.92 to 45.45) | 16.7 (0.42 to 64.12) |
| PD-L1: >=50% | 0 (0.00 to 45.93) | 42.9 (9.90 to 81.59) | 0 (0.00 to 70.76) |
| hs-CRP: <2mg/L | 12.5 (0.32 to 52.65) | 7.7 (0.19 to 36.03) | 37.5 (8.52 to 75.51) |
| hs-CRP: >=2mg/L | 0 (0.0 to 13.23) | 22.7 (7.82 to 45.37) | 0 (0.00 to 33.63) |
| hs-IL-6: <Q1 (2.52 mg/L) | 16.7 (0.42 to 64.12) | 12.5 (0.32 to 52.65) | 14.3 (0.36 to 57.87) |
| hs-IL-6: >=Q1 (2.52 pg/mL) to <Q2 (5.36 pg/mL) | 0 (0.00 to 36.94) | 10 (0.25 to 44.50) | 33.3 (0.84 to 90.57) |
| hs-IL-6: >=Q2 (5.36 pg/mL) to <Q3 (12.03 pg/mL) | 0 (0.00 to 36.94) | 28.6 (3.67 to 70.96) | 16.7 (0.42 to 64.12) |
| hs-IL-6: >=Q3 (12.03 pg/mL) | 0 (0.00 to 30.85) | 20.0 (2.52 to 55.61) | 0 (0.00 to 97.50) |
| CD8: <3% | 0 (0.00 to 26.46) | 13.0 (2.78 to 33.59) | 0 (0.00 to 52.18) |
| CD8: >=3% | 0 (0.00 to 18.53) | 22.2 (2.81 to 60.01) | 33.3 (4.33 to 77.72) |
Collected over From day of first dose of study medication to 130 days after last dose of study medication, up to 25.6 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Canakinumab Monotherapy | 3/35 (8.6%) | 10/35 (28.6%) | 28/35 (80%) |
| Canakinumab + Pembrolizumab | 2/35 (5.7%) | 9/35 (25.7%) | 27/35 (77.1%) |
| Pembrolizumab Monotherapy | 1/18 (5.6%) | 4/18 (22.2%) | 14/18 (77.8%) |
| Event | Canakinumab Monotherapy | Canakinumab + Pembrolizumab | Pembrolizumab Monotherapy |
|---|---|---|---|
| PneumoniaInfections and infestations | 3/35 | 1/35 | 0/18 |
| COVID-19Infections and infestations | 2/35 | 1/35 | 1/18 |
| HypothyroidismEndocrine disorders | 0/35 | 0/35 | 1/18 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/35 | 0/35 | 1/18 |
| HaemothoraxRespiratory, thoracic and mediastinal disorders | 0/35 | 0/35 | 1/18 |
| RashSkin and subcutaneous tissue disorders | 0/35 | 0/35 | 1/18 |
| ArrhythmiaCardiac disorders | 1/35 | 0/35 | 0/18 |
| Cardiac failureCardiac disorders | 1/35 | 0/35 | 0/18 |
| Myocardial ischaemiaCardiac disorders | 1/35 | 0/35 | 0/18 |
| Immune-mediated hepatitisHepatobiliary disorders | 0/35 | 1/35 | 0/18 |
| Event | Canakinumab Monotherapy | Canakinumab + Pembrolizumab | Pembrolizumab Monotherapy |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 9/35 | 1/35 | 1/18 |
| FatigueGeneral disorders | 9/35 | 5/35 | 4/18 |
| DiarrhoeaGastrointestinal disorders | 1/35 | 6/35 | 0/18 |
| Procedural painInjury, poisoning and procedural complications | 0/35 | 6/35 | 2/18 |
| Decreased appetiteMetabolism and nutrition disorders | 6/35 | 1/35 | 0/18 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/35 | 6/35 | 2/18 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/35 | 6/35 | 1/18 |
| NauseaGastrointestinal disorders | 4/35 | 3/35 | 3/18 |
| SARS-CoV-2 test negativeInvestigations | 2/35 | 3/35 | 3/18 |
| HyperthyroidismEndocrine disorders | 0/35 | 5/35 | 1/18 |
| Age, Continuous(Years) | Canakinumab Monotherapy | Canakinumab + Pembrolizumab | Pembrolizumab Monotherapy | Total |
|---|---|---|---|---|
| Mean | 65.5 ± 9.88 | 67.1 ± 6.98 | 66.1 ± 5.61 | 66.2 ± 7.99 |
| Sex: Female, Male(Participants) | Canakinumab Monotherapy | Canakinumab + Pembrolizumab | Pembrolizumab Monotherapy | Total |
|---|---|---|---|---|
| Female | 13 | 14 | 9 | 36 |
| Male | 22 | 21 | 9 | 52 |
| Race/Ethnicity, Customized(Participants) | Canakinumab Monotherapy | Canakinumab + Pembrolizumab | Pembrolizumab Monotherapy | Total |
|---|---|---|---|---|
| White | 20 | 25 | 12 | 57 |
| Asian | 7 | 3 | 2 | 12 |
| Black or African American | 1 | 1 | 0 | 2 |
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Unknown | 7 | 5 | 4 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Ran from Nov 2019 to primary completion in Apr 2022, 29 months.
Results were first posted in Jul 2023, 1 year 2 months after primary completion. A results delay was requested in Jul 2022.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Canakinumab · Pembrolizumab
Carcinoma, Non-Small-Cell Lung →